- Home
- ZCMD vs ICCM Comparison
ZCMD vs ICCM Comparison
Compare ZCMD & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZCMD | ICCM |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 8.3M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ZCMD | ICCM |
|---|---|---|
| Price | $1.39 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.67 |
| AVG Volume (30 Days) | ★ 237.7K | 166.3K |
| Earning Date | 12-22-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $27.11 |
| Revenue Next Year | N/A | $104.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.13 |
| 52 Week High | $11.96 | $9.54 |
Technical Indicators
Market Signals| Indicator | ZCMD | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 17.54 |
| Support Level | $1.31 | $0.22 |
| Resistance Level | $1.69 | $2.50 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 46.36 | 10.45 |
Price Performance
Historical ComparisonAbout ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.